Novo Nordisk A/S (NYSE:NVO) Shares Sold by HCR Wealth Advisors

HCR Wealth Advisors cut its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 2.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 11,720 shares of the company’s stock after selling 234 shares during the period. HCR Wealth Advisors’ holdings in Novo Nordisk A/S were worth $1,008,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Natixis Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after acquiring an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC lifted its position in Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after purchasing an additional 19,870 shares during the period. Versant Capital Management Inc purchased a new stake in Novo Nordisk A/S in the 4th quarter valued at approximately $86,000. Talbot Financial LLC acquired a new position in Novo Nordisk A/S during the 4th quarter worth approximately $4,066,000. Finally, Zions Bancorporation N.A. raised its stake in shares of Novo Nordisk A/S by 57.0% during the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after buying an additional 6,726 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $82.99 on Thursday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company’s 50-day moving average price is $99.26 and its 200 day moving average price is $118.18. Novo Nordisk A/S has a 52 week low of $80.05 and a 52 week high of $148.15. The stock has a market cap of $372.42 billion, a price-to-earnings ratio of 26.86, a PEG ratio of 0.92 and a beta of 0.45.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.